|
|||||
|
|
Platinum rechallenge in recurrent head and neck squamous cell carcinoma after primary chemoradiation |
|
| Authors: | A. Rambeau I. Licaj B. Gery R. Gervais C. Florescu E. Babin D. De Raucourt A. Johnson J. Thariat |
| Affiliation: | 1. Head and Neck Oncology, Centre François Baclesse, Avenue du Général Harris, 14000 Caen, France;2. Medical Oncology Department, Centre François Baclesse, Caen, France;3. Clinical Research Department, Centre François Baclesse, Caen, France;4. Radiotherapy Department, Centre Francois Baclesse, Caen, France;5. Head and Neck Surgery Department, University Hospital, Caen, France;6. Head and Neck Surgery Department, Centre François Baclesse, Caen, France |
| Abstract: | ObjectiveTo evaluate platinum rechallenge efficacy and tolerance in patients presenting recurrent head and neck squamous cell carcinoma (HNSCC) after platinum-based chemoradiation.Materials and methodsWe retrospectively included all patients treated from 2007 to 2016 by platinum-based polychemotherapy for recurrence of HNSCC previously treated by primary or postsurgical platinum-based chemoradiation. The primary end-point was disease control rate (DCR) on platinum rechallenge.ResultsForty-five patients were included. Median disease-free interval (DFI) after chemoradiation was 5.7 months. DCR on platinum rechallenge was 40%. Progression-free survival at recurrence was 3.7 months and overall survival 5.0 months. DCR in patients with recurrence within 6 months of chemoradiotherapy was 47.8%. DFI > 4.5 months was associated with better DCR: 28.5% versus 54.8%; P = 0.0311.ConclusionPlatinum rechallenge provided good DCR in recurrent HNSCC after chemoradiation. |
| Keywords: | Corresponding author. Head and Neck Oncology, Centre François Baclesse, Avenue du Général Harris, 14000 Caen, France. Head and neck cancer Recurrence Cisplatin Carboplatin |
| 本文献已被 ScienceDirect 等数据库收录！ | |